Journal: bioRxiv
Article Title: The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
doi: 10.1101/2024.08.08.606661
Figure Lengend Snippet: (A) K18-hACE2 mice were intranasally infected and intraperitoneally dosed as indicated with either vehicle (n=10) or AVI-4206 (n=15). Mice infected with WA1 N40D mutant, which lacks Mac1 catalytic activity, served as a positive control (n=10). Lungs were harvested at indicated time points for virus titration by plaque assay. (B) The percent body weight loss for all animals. The data are presented as mean ± SD. (C) Survival curve plotted based on the percent weight loss humane endpoint. (D) Viral load in the lungs and brain of infected mice at the indicated time points. The data are shown as mean ± s.e.m. *, P < 0.05; **, P < 0.01 by Mann Whitney’s test relative to the vehicle control. (E) Schematics and graphs demonstrating the abundance of indicated cytokines at 4 and 7 days post-infection in the lungs of infected mice. The data are presented as mean ± s.e.m. *, P < 0.05; **, P < 0.01 by two-tailed Student’s t-test relative to the vehicle control at each timepoint. None of the mice reached the humane endpoint at day 4 post-infection. For mice that reached the humane endpoint before day 7 post-infection, the tissues were collected and analyzed with mice at the 7 day time point.
Article Snippet: A549-ACE2h cells were generated by stably expressing hACE2 ( ) and further selecting for high ACE2 expression levels via FACS with Alexa Fluor® 647 conjugated to a hACE2-specific antibody (FAB9332R, R&D systems).
Techniques: Infection, Mutagenesis, Activity Assay, Positive Control, Virus, Titration, Plaque Assay, Control, Two Tailed Test